• Adrian Simpson, United States says, "If you are looking for a fair deal on medical supplies, IDM is something I would seriously recommend. Am hooked for life."
  • Craig, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "IDM makes online shopping a pleasure. Shopping is so simple that you just breeze through it."
  • Harry Mason, United States says, "I have to admit am a bit of a lazy bloke when it comes to ordering online .And IDM pampers me to the hit as it's so simple to order."
  • John Hanks, United States says, "I was a sceptic until my first order. After, I received my first package, I turned believer. Now, it’s been 3 years since I have been ordering from IDM."
  • Natalie Wallace, United States says, "I was apprehensive about how my doubts would be addressed but what the heck,I went ahead and placed my order. Customer service was patient and helped me out."
  • Mark Penning, United States says, "Happy I got my package just in time for my vacation. Needless to say, it made my holiday a wonderfully satisfying experience."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    You can find the latest happening of our pharmacy
    Follow us on Twitter
    You are here: Home > Pharmacy News | Health Articles/Tips > Ranbaxy Laboratories > September 08, 2009

      Ranbaxy's Romania unit to market osteoporosis drug

      Posted AtBusiness-Standard.com

      Pharma firm Ranbaxy Laboratories today said its Romanian arm will market Evista, a drug used for treating osteoporosis.

      Terapia SA (Terapia Ranbaxy), a subsidiary of the company would market the osteoporosis medication drug in Romania, Ranbaxy Laboratories, which was acquired by Daiichi Sankyo last year, said in a filing to the Bombay Stock Exchange.

      "The launch of Evista by Terapia Ranbaxy in Romania marks our first international endeavour as a global partnership. Terapia Ranbaxy is a strong player in Europe, and we will provide a unique platform to Daiichi Sankyo for the launch of Evista, and many more new products in the future," Ranbaxy CEO and Managing Director Atul Sobti said.

      Terapia Ranbaxy is the largest generic pharmaceutical company.

      "We continue to explore other collaborations with Ranbaxy that will help optimise our growth," Daiichi Sankyo President and CEO Takashi Shoda said.

      In 2006, Daiichi Sankyo acquired the marketing and distribution rights for Evista, an osteoporosis treatment, in six European countries from Eli Lilly and Company, it said.

      In 2008, Daiichi Sankyo acquired additional rights for the drug covering all remaining countries in Europe, with the exception of Greece, the filing said.

      Shares of Ranbaxy Laboratories were trading at Rs 332 on the BSE, up 1.34 per cent from previous close.

      September 08, 2009


      Share this Article!

    Back to top^